Financial Performance - Total revenues for Q2 2022 were $175.8 million, a decrease of 2.3% compared to $180.0 million in Q2 2021[24]. - Product revenues decreased to $130.3 million in Q2 2022 from $141.0 million in Q2 2021, representing a decline of 4.9%[24]. - Service revenues increased to $45.5 million in Q2 2022, up 16.7% from $39.0 million in Q2 2021[24]. - The company reported a net loss of $58.6 million for the three months ended June 30, 2022, compared to a net loss of $53.9 million for the same period in 2021[157]. - For the six months ended June 30, 2022, total revenues were $339.0 million, a decrease of 2.1% from $346.2 million in the same period of 2021[148]. - The company experienced a net loss of $59.3 million for the three months ended June 30, 2022, compared to a net loss of $54.0 million for the same period in 2021, representing an increase in losses of approximately 9.8%[196]. - Net loss for the six months ended June 30, 2022, improved to $78.3 million from a loss of $94.7 million in the same period of 2021, representing a 17.5% reduction[199]. Expenses and Profitability - Gross profit for Q2 2022 was $79.0 million, slightly down from $79.6 million in Q2 2021[24]. - Operating expenses surged to $153.6 million in Q2 2022, compared to $74.9 million in Q2 2021, primarily due to a $55.2 million goodwill impairment[24]. - Selling, general and administrative expenses increased to $91.0 million in the Successor Period from $66.7 million in the Predecessor Period, reflecting a rise of 36.5%[216]. - Adjusted EBITDA for the three months ended June 30, 2022, was $42.6 million, down from $49.9 million in the same period of 2021, indicating a decline of about 6.3%[196]. - Adjusted EBITDA for the six months ended June 30, 2022, was $77.5 million, down 13.4% from $89.9 million in the same period of 2021[204]. Assets and Liabilities - Total assets decreased to $2,916.9 million as of June 30, 2022, down from $3,118.0 million at the end of 2021[22]. - Total liabilities were $1,258.0 million as of June 30, 2022, a decrease from $1,334.0 million at the end of 2021[22]. - Stockholders' equity decreased to $1,658.9 million as of June 30, 2022, down from $1,784.0 million at the end of 2021[22]. - Total accrued expenses and other current liabilities amounted to $73.6 million as of June 30, 2022, a decrease from $75.4 million at December 31, 2021[70]. Goodwill and Impairments - The company incurred a goodwill impairment of $55.2 million during the six months ended June 30, 2022[34]. - The total goodwill balance decreased to $1,566.6 million from $1,662.6 million as of December 31, 2021, reflecting a goodwill impairment of $55.2 million in the Industrial segment[79]. - A goodwill impairment charge of $55.2 million was recorded in the Industrial segment during the Successor Period[218]. Segment Performance - Medical segment revenues for the three months ended June 30, 2022, were $66.8 million, up from $52.1 million in the prior year[145]. - Industrial segment revenues for the three months ended June 30, 2022, were $109.0 million, down from $127.9 million in the same period of 2021[145]. - Medical segment revenues for the six months ended June 30, 2022, were $126.9 million, while Industrial segment revenues were $212.1 million[204]. Cash Flow and Liquidity - Operating cash flow for the six months ended June 30, 2022, was $28.0 million, down from $33.7 million in the prior year, indicating a decrease of 16.9%[34]. - Cash, cash equivalents, and restricted cash at the end of the period were $92.0 million, up from $85.3 million at the beginning of the period, marking an increase of 7.8%[34]. - Cash paid for interest during the six months ended June 30, 2022, was $13.9 million[126]. Backlog and Future Outlook - The backlog as of June 30, 2022, was $692.7 million, a decrease from $747.5 million as of December 31, 2021[185]. - The company plans to continue focusing on expanding its medical segment and enhancing its product offerings in the upcoming quarters[148]. - The company has a backlog driven by contracts for new nuclear power plant construction, providing a strong pipeline for future revenue recognition in the Industrial segment[190]. Other Financial Metrics - The effective income tax rate for the three months ended June 30, 2022, was 11.1%, compared to (36.4)% for the same period in 2021[124]. - The company recognized an unrealized gain of $39.5 million due to a decrease in the fair value of warrant liabilities for the six months ended June 30, 2022[155]. - The fair value of public warrants was measured at $19.7 million as of June 30, 2022, based on the listed market price[153].

Mirion Technologies, Inc. (NYSE:MIR) Q2 2022 Earnings Conference Call July 29, 2022 10:00 AM ET Company Participants Alex Gaddy - Vice President, Finance & Investor Relations Larry Kingsley - Chairman Tom Logan - Chief Executive Officer Brian Schopfer - Chief Financial Officer Conference Call Participants Andy Kaplowitz - Citigroup Joe Ritchie - Goldman Sachs Chris Moore - CJS Securities Operator Greetings. Welcome to Mirion Technologies Incorporated Fiscal Second Quarter 2022 Earnings Conference Call. At t ...

MIRION TECHNOLOGIES MIR LISTED NYSE Fiscal Second Quarter Ended June 30, 2022 Earnings Presentation July 29, 2022 Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "continue," "could," "estimate", "expect", "hope", "intend", "may", "might", "should", "would", "will", "understand" and similar words are intend ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39352 Mirion Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 83-0974996 (State or ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $163.2 million, representing a decline of 4.3% compared to Q1 2021, with adjusted EBITDA down 12.5% [24][25] - Organic revenue declined by 4.2%, with adjusted EBITDA margin contracting by 200 basis points to 21.4% [24][25] - Adjusted EPS for the quarter was $0.10, slightly better than expectations due to lower taxes [25] Business Line Data and Key Metrics Changes - Medical segment adjusted revenue increased by 7.7%, with organic growth of 0.7%, but was negatively impacted by supply chain challenges [26] - Industrial segment reported a 10.1% decline in adjusted revenue, with organic revenue down 6.6% [27] - Strong growth in nuclear medicine and dosimetry was noted, but overall performance was offset by supply chain disruptions [21][26] Market Data and Key Metrics Changes - Core orders grew approximately 19% year-over-year, adjusted for foreign exchange impacts, indicating robust demand across both industrial and medical segments [12][33] - The outlook for the nuclear power industry has improved, with increased government support and rising natural gas prices driving demand [12][15] - The defense segment is expected to see increased demand due to heightened military and civil defense concerns stemming from the Ukraine conflict [16][17] Company Strategy and Development Direction - The company aims to deliver inorganic growth of 5 to 10 points and has a strong M&A pipeline [22] - Focus on digitization and new product launches in the medical segment, including the introduction of SunCHECK and SunSCAN [18] - The company has removed all remaining Russian-related revenue from projections, reflecting a cautious approach to geopolitical dynamics [20] Management's Comments on Operating Environment and Future Outlook - The operating environment remains challenging due to supply chain issues and geopolitical tensions, but the company is well-positioned for growth [6][9] - Management expressed confidence in the ability to navigate short-term hurdles, citing a strong backlog and healthy end markets [22][33] - Future growth is expected to be supported by favorable market conditions in nuclear power and defense sectors [12][15][16] Other Important Information - The company generated $10 million of adjusted free cash flow in Q1 2022, a slight improvement from the previous year [28] - Updated guidance for 2022 reflects a revised adjusted revenue growth expectation of 3.5% to 5.5%, down from 5.5% to 7.5% [29][30] - Adjusted EBITDA target range for 2022 has shifted to $170 million to $180 million, reflecting the removal of Russian-related EBITDA [30][31] Q&A Session Summary Question: Supply chain challenges in the Medical segment - Management confirmed that supply chain issues have shifted towards radiation therapy and nuclear medicine, with proactive measures in place to address these challenges [36] Question: Pricing escalators in contracts - Management indicated that most contracts have pricing escalators, but there is a lag in price adjustments, with expectations for improvement in the latter half of the year [37][38] Question: New construction's impact on nuclear revenue - Management expects the percentage of revenue from new construction to increase due to favorable conditions in the nuclear industry [40] Question: Incremental defense and nuclear EBITDA - Management provided insights into the expected $10 million increase in defense and nuclear EBITDA, citing strong order dynamics and government support [46][65] Question: Order trends and conversion into earnings - Management noted that the 19% growth in core orders reflects strength across segments, with expectations for gradual conversion into earnings over the coming quarters [50][63] Question: Cash flow generation and leverage - Management emphasized a focus on generating cash flow to tackle leverage, with expectations for improved cash generation in the latter half of the year [72] Question: Direct exposure to supply chain issues in China - Management clarified that direct exposure to China is limited, with proactive measures in place to mitigate supply chain risks [74]

Financial Performance - The Business Combination consideration paid by the Company to pre-Business Combination stockholders was approximately $1.3 billion in cash, along with 30,401,902 newly issued shares of Class A common stock and 8,560,540 newly issued shares of Class B common stock[31]. - Approximately 19.5% of GSAH's issued and outstanding Class A common stock was redeemed by stockholders prior to the Business Combination[28]. - The Company’s financial performance is driven by the replacement of products and recurring services in core end markets, as well as the construction of new nuclear power plants globally[27]. - Approximately 45% of total revenue for fiscal 2021 came from sales to customers outside the United States and Canada, highlighting the company's global footprint and market reach[78]. - Total backlog as of December 31, 2021, was $747.5 million, an increase from $715.8 million on June 30, 2021[92]. - Deferred contract revenue increased to $73.0 million as of December 31, 2021, compared to $50.4 million on June 30, 2021[92]. - Approximately 45% of the backlog is expected to be recognized in calendar year 2022[91]. - The top five customers accounted for approximately 14% of consolidated revenue during the reporting periods[101]. Market Opportunities - The Company aims to capitalize on growth opportunities in medical, defense, and nuclear power sectors[26]. - The global nuclear medicine market is expected to grow approximately 7% per year from 2020 through 2030, driven by the increase in cancer prevalence and incidences[58]. - The global radiotherapy market is projected to grow approximately 6% per year from 2020 through 2030, influenced by growing awareness and technological advancements[58]. - The core dosimetry market is expected to grow 3 to 4% per year from 2020 through 2026, driven by an increase in healthcare workers exposed to radiation[59]. - The existing global installed base of nuclear reactors has a median age of 34 years, necessitating frequent product replacements and upgrades[65]. - The total number of nuclear power plant shutdowns under decontamination and decommissioning is expected to increase over the next decade, particularly in the U.S. market[66]. - The global nuclear reactor construction market is expected to grow, with 57 reactors currently under construction and 423 planned or proposed, providing significant revenue opportunities for the company[69]. - The company aims to exploit under-penetrated market opportunities, particularly in the U.S. dosimetry services market and the nuclear sector in Europe[81]. Product Development and Innovation - The Company has successfully leveraged its expertise in ionizing radiation to drive innovation and expand commercial applications[22]. - New product development includes the evrCAM for radiation oncology, leveraging core technology from the nuclear power industry[83]. - The company has developed a new personal radiation detector, Accurad, to expand its presence in civil services markets such as police and fire departments[84]. - The company has successfully integrated fourteen acquisitions since 2016, enhancing its product offerings and market presence in the radiation detection sector[79]. Regulatory Compliance - The company is subject to various environmental regulations, including the Comprehensive Environmental Response, Compensation and Liability Act, which may impose future remediation expenditures[117]. - The company must comply with the Resource Conservation and Recovery Act, which regulates hazardous waste management and imposes civil liabilities for non-compliance[117]. - The company is subject to inspections by the Nuclear Regulatory Commission to ensure compliance with safety and quality assurance regulations in the nuclear power industry[131]. - The company holds numerous licenses for radioactive materials across various jurisdictions, with typical license terms ranging from two to five years[129]. - The company incurs costs associated with obtaining and maintaining approvals for medical devices from regulatory bodies such as the FDA and the European Medicines Agency[147]. - Medical devices must comply with the FDA's regulations, including safety and effectiveness standards, and any significant changes may require new approvals[149]. - The company must navigate complex regulatory requirements for marketing medical devices in non-U.S. countries, which can vary significantly[154]. - Compliance with privacy and information security laws, such as the GDPR and CCPA, is essential for the company as it processes personal information[161]. Workforce and Operations - The engineering and research and development organization consists of 356 scientists, engineers, and technicians, representing approximately 14% of the workforce as of December 31, 2021[26]. - The company employed 2,630 full-time and part-time employees as of December 31, 2021[105]. - The production personnel consisted of 1,176 employees, representing approximately 45% of the total workforce as of December 31, 2021[102]. - The company has a seasoned management team with an average tenure of over 15 years, supported by a skilled engineering and R&D organization of 356 professionals[80]. - The company has 30 sales offices across North America, Europe, and Asia as of December 31, 2021[96]. Economic Factors - The company is experiencing inflationary pressure on operating costs, including increased personnel costs and higher commodity prices[601]. - Freight costs for inbound and outbound shipments have increased, expected to persist into 2022[602]. - A hypothetical 10% change in foreign currencies would have impacted revenues by approximately $8.7 million during the Successor Period[598]. - The effect of a hypothetical 1% change in exchange rates would have impacted accumulated other comprehensive income by approximately $2.5 million during the Successor Period[599]. - If market interest rates increase by 100 basis points, year-to-date interest expense would increase by approximately $8.4 million[600]. - Changes in foreign exchange rates could impact the price and demand for products, affecting competitiveness[599]. Compliance and Legal Risks - The company is affected by multi-jurisdictional legal and regulatory environments, which impose extensive and changing laws governing its operations[121]. - The company is subject to various economic sanctions imposed by the U.S. Treasury Department's Office of Foreign Assets Control (OFAC), which restrict transactions with certain countries and entities[138]. - Violations of U.S. export control regulations or OFAC sanctions can lead to significant penalties, including criminal and civil fines, imprisonment, and loss of export privileges[140]. - The company has implemented compliance policies and procedures to address challenges related to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act[144].

Mirion Technologies, Inc. (NYSE:MIR) Q4 2021 Earnings Conference Call February 23, 2022 10:00 AM ET Company Representatives Larry Kingsley - Chairman Tom Logan - Founding, Chief Executive Officer Brian Schopfer - Chief Financial Officer Alex Gaddy - Vice President of Finance, Investor Relations Conference Call Participants Joe Ritchie - Goldman Sachs Ronny Scardino - Goldman Sachs Operator Greetings! And welcome to Mirion Technologies Fourth Quarter and Full Year 2021 Earnings Conference Call. At this time ...

MIRITO N TECHNOLOGIES MIR LISTED NYSE Fiscal Quarter and Fiscal Year Ended December 31, 2021 Earnings Presentation February 23, 2022 Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "continue," "could," "estimate", "expect", "hope", "intend", "may", "might", "should", "would", "will", "understand" and simil ...

Financial Position - As of September 30, 2021, the company had current assets of $750,621,780 and current liabilities of $99,502,777[133]. - The company had cash held in a custodian account of $195,542 and working capital of $651,119,003 as of September 30, 2021[148]. - The company has no long-term debt or off-balance sheet arrangements as of September 30, 2021[152]. Business Combination - The company completed its business combination on October 20, 2021, with a total consideration of $1.3 billion in cash and newly issued shares[137]. - Stockholders elected to redeem 14,628,610 shares of Class A common stock, representing approximately 19.5% of the issued and outstanding shares before the business combination[135]. - After the business combination, there were 199,523,292 shares of Class A common stock and 8,560,540 shares of Class B common stock issued and outstanding[141]. Financial Performance - For the nine months ended September 30, 2021, the company reported a net loss of $(10,341), with general and administrative expenses primarily related to the proposed business combination totaling $(11,631,971)[145]. - The company incurred expenses of $90,000 under an administrative support agreement for the nine months ended September 30, 2021[154]. Capital Raising - The company raised $900,000,000 through a PIPE investment, subscribing for 90,000,000 shares of Class A common stock[140]. - The underwriters of the public offering received underwriting discounts and commissions of 5.5%, totaling $41,250,000, with $15,000,000 paid at closing and $26,250,000 deferred[155]. Securities and Derivatives - As of September 30, 2021, the company had outstanding warrants to purchase up to 27,250,000 shares of Class A common stock, which were excluded from the diluted net income per share calculation due to contingent exercise conditions[158]. - All 75,000,000 shares of Class A common stock sold in the Public Offering contained a redemption feature and were classified as redeemable securities[159]. - The company accounts for warrants as derivative liabilities, adjusting their fair value at each reporting period, with changes recognized in the statement of operations[160]. Risk Management - The net proceeds from the Public Offering and Private Placement Warrants were invested in money market funds, resulting in no material exposure to interest rate risk as of September 30, 2021[165]. - The company has not engaged in any hedging activities since inception and does not expect to do so regarding market risk[166].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39352 GS Acquisition Holdings Corp II (Exact name of registrant as specified in its charter) (State or other jurisdic ...